- Investing Ideas
- Indian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Indian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
7
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
7 companies
Alembic Pharmaceuticals
Market Cap: ₹162.2b
An integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally.
APLLTD
₹825.10
7D
-1.5%
1Y
-20.0%
Strides Pharma Science
Market Cap: ₹99.1b
Develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally.
STAR
₹1,074.90
7D
-0.7%
1Y
21.9%
Vimta Labs
Market Cap: ₹25.0b
Provides contract research and testing services in India and internationally.
524394
₹559.50
7D
-1.2%
1Y
6.4%
Lincoln Pharmaceuticals
Market Cap: ₹11.9b
Engages in manufacturing and trading of pharmaceutical products in India.
531633
₹594.95
7D
-3.7%
1Y
6.4%
CCME Global
Market Cap: ₹5.1b
Does not have significant operations.
514336
₹113.55
7D
-1.2%
1Y
362.5%
Haleos Labs
Market Cap: ₹4.7b
Engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India.
HALEOSLABS
₹1,571.10
7D
-1.6%
1Y
26.2%
Par Drugs and Chemicals
Market Cap: ₹1.3b
Develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India.
PAR
₹104.93
7D
17.1%
1Y
-1.2%